Astria Therapeutics, Inc. - Common Stock (NQ:ATXS)

12.58 UNCHANGED

Last Price Updated: 4:00 PM EST, Jan 22, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Astria Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Astria Therapeutics Presents New Phase 1a Data Confirming Potential for STAR-0125 to Prevent Hereditary Angioedema Attacks with Dosing 2 or 4 Times Per Year at the 2023 American College of Allergy, Asthma, and Immunology Annual Scientific Meeting

November 10, 2023

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference

November 09, 2023

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics to Present New STAR-0215 Data at the 2023 American College of Allergy, Asthma, And Immunology Annual Scientific Meeting

November 03, 2023

From Astria Therapeutics, Inc.

Via Business Wire

Expert Ratings for Astria Therapeutics ↗

October 13, 2023

Via Benzinga

Astria Therapeutics: Q1 Earnings Insights ↗

May 11, 2023

Via Benzinga

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 02, 2023

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Monday, November 13th

October 30, 2023

From Astria Therapeutics, Inc.

Via Business Wire

HC Wainwright & Co. Maintains Buy Rating for Astria Therapeutics: Here's What You Need To Know ↗

October 12, 2023

Via Benzinga

Exxon Mobil To Rally Around 23%? Here Are 10 Other Analyst Forecasts For Thursday ↗

October 12, 2023

Cantor Fitzgerald cut Hyliion Holdings Corp. (NYSE: HYLN) price target from $2 to $1. Cantor Fitzgerald analyst Andres Sheppard downgraded the stock from Neutral to Underweight. Hyliion shares fell...

Via Benzinga

Astria Therapeutics Announces Pricing of $64 Million Underwritten Offering

October 11, 2023

From Astria Therapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

October 11, 2023

Via Benzinga

Astria Therapeutics Announces Exclusive Worldwide License Agreement with Ichnos Sciences for OX40 Portfolio

October 11, 2023

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 03, 2023

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics to Participate in Upcoming Investor Conferences

September 06, 2023

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics Announces Publication of STAR-0215 Preclinical Data in the Journal of Pharmacology and Experimental Therapeutics

August 31, 2023

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics to Present Patient Survey Data at Upcoming 2023 HAEi Regional EMEA Conference

August 25, 2023

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update

August 07, 2023

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 02, 2023

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics Receives Fast Track Designation for STAR-0215 for the Treatment of Hereditary Angioedema

July 20, 2023

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics Names John Ruesch as Senior Vice President, Pharmaceutical Sciences and Technical Operations

July 17, 2023

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics to Present Patient Survey Data at Upcoming 2023 US HAEA National Summit

July 14, 2023

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 06, 2023

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 06, 2023

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics to Present STAR-0215 at the 2023 European Academy of Allergy, Asthma, and Immunology Annual Meeting

June 05, 2023

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference

May 31, 2023

From Astria Therapeutics

Via Business Wire

Astria Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update

May 11, 2023

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 02, 2023

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics to Present STAR-0215 at the 13th C1-Inhibitor Deficiency and Angioedema Workshop

April 28, 2023

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics Names Andrea Matthews Chief Business Officer

April 19, 2023

From Astria Therapeutics, Inc.

Via Business Wire

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 04, 2023

From Astria Therapeutics, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.